Skip to content
10-Q

Quarterly Report

NEUMORA THERAPEUTICS, INC. NMRA

0000950170-25-069311

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2025 161.75M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $28.38M
Current Liabilities Q1 2025 · Dec 31, 2024 $29.89M
Total Liabilities Q1 2025 · Mar 31, 2025 $28.38M
Total Liabilities Q1 2025 · Dec 31, 2024 $29.91M
Current Assets Q1 2025 · Mar 31, 2025 $254.87M
Current Assets Q1 2025 · Dec 31, 2024 $314.06M
Total Assets Q1 2025 · Mar 31, 2025 $256.75M
Total Assets Q1 2025 · Dec 31, 2024 $316.97M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $142.15M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $182.93M
Shares Diluted Q1 2025 · Mar 31, 2024 157.94M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$42.96M
Stockholders Equity Q1 2025 · Mar 31, 2024 $424.54M
Stockholders Equity Q1 2025 · Dec 31, 2023 $469.08M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.34
Eps Basic Q1 2025 · Mar 31, 2024 −$0.34
Sga Expense Q1 2025 · Mar 31, 2024 $14.32M
Rd Expense Q1 2025 · Mar 31, 2024 $45.76M
Net Income Q1 2025 · Mar 31, 2024 −$53.72M
Operating Income Q1 2025 · Mar 31, 2024 −$60.07M